PsiQuantum and National Cancer Center Japan Partner to Advance Cancer Treatment Research

PsiQuantum has entered a collaborative research agreement with the National Cancer Center Japan to accelerate drug discovery using utility-scale quantum computers, a partnership intended to improve research, resource allocation, and patient outcomes in cancer treatment. The collaboration will focus on advancing fault-tolerant quantum algorithm development and creating clinically relevant applications, utilizing PsiQuantum’s software suite, Construct, for algorithm design and optimization. “PsiQuantum is proud to work alongside the National Cancer Center Japan as we explore what utility-scale quantum computing can deliver in designing new treatments for the benefit of researchers and patients,” said Sam Pallister, PsiQuantum’s Vice President for Quantum Applications. Pharmaceutical research and development is often lengthy and costly; PsiQuantum and the National Cancer Center Japan aim to overcome these hurdles by simulating molecular systems with greater accuracy and speed, potentially transforming how new medicines are created. PsiQuantum and National Cancer Center Japan Oncology Collaboration The partnership, formalized through a research agreement, aims to advance fault-tolerant quantum algorithm development and create clinically relevant applications, addressing a critical need for faster, more reliable drug discovery processes. Current methods struggle to deliver timely results, contributing to the high cost and extended duration of bringing new treatments to market; PsiQuantum’s technology promises to simulate molecular systems with a level of accuracy previously difficult to achieve. This initiative will also incorporate PsiQuantum’s Construct software, a platform designed for algorithm design, analysis, and optimization for fault-tolerant quantum computing, facilitating a secure end-to-end workflow. Dr. Takayuki Yoshino, Director for the Department of Global Oncology at the National Cancer Center Hospital East, emphasized the potential for innovation, stating, “Together, our teams are poised to conduct research and unlock new solutions at the intersection of pharmaceuticals, biotechnology, and quantum computing.” The collaboration intends to accelerate research, reduce development costs, and ultimately improve patient outcomes through quantum simulation. Construct Platform Advances Fault-Tolerant Quantum Algorithm Development Construct is not merely a software tool, but a secure end-to-end environment intended to bridge the gap between theoretical quantum computation and tangible healthcare solutions, specifically within oncology. This partnership acknowledges the limitations of current computational methods in pharmaceutical research, where lengthy development cycles and high costs impede progress; utility-scale quantum computers offer the potential to simulate molecular interactions with a precision previously unattainable, promising to accelerate drug discovery and reduce associated expenses. Dr. We are thrilled to partner with PsiQuantum on leveraging quantum computing technology to address some of the most pressing challenges in healthcare. Dr. Takayuki Yoshino, Director for the Department of Global Oncology at the National Cancer Center Hospital East in Kashiwa, Japan Source: https://www.psiquantum.com/news-import/ncc-japan-partnership-announcement DRUG DISCOVERY NATIONAL CANCER CENTER JAPAN ONCOLOGY PSIQUANTUM QUANTUM COMPUTING